BioCentury
ARTICLE | Company News

Genzyme, Wyeth sales and marketing update

November 8, 2004 8:00 AM UTC

GENZ acquired from WYE sales and marketing rights for osteoarthritis drug Synvisc hylan G-F 20 in the U.S. and five European countries (Germany, Poland, Greece, Portugal and the Czech Republic). In exchange, WYE will receive $121 million in cash up front plus milestone payments based on the volume of Synvisc sales. These payments could extend out to June 2012 or total up to $294 million, whichever comes first. GENZ estimates that the drug will post $240 million in worldwide sales this year. ...